Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Two-year prognosis of admission hemoglobin A1c following a primary percutaneous coronary intervention

Çiçek, Gökhan; Korkmaz, Ahmet

doi: 10.1097/MCA.0000000000000411
Original Research
Buy

Objective We sought to assess the effect of hemoglobin A1c (HbA1c) on the outcomes of a primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).

Background Many studies have shown the diagnostic and predictive value of HbA1c levels in patients with acute myocardial infarction. We assessed the prognostic role of HbA1c in short-term and long-term mortality in 796 consecutive patients with STEMI.

Methods and results A total of 796 patients with STEMI undergoing primary PCI were prospectively enrolled between December 2013 and June 2015. The patients were divided into three groups on the basis of admission HbA1c levels: group I (HbA1c≤5.6%), group II (HbA1c 5.7–6.4%), and group III (HbA1c≥6.5%). The in-hospital and 2-year cardiovascular (CV) mortality and morbidity of all three patient groups were followed up. A significant association was found between HbA1c level and 2-year primary clinical outcomes, including CV mortality, heart failure/shock, and major adverse cardiovascular event (P<0.001).

Conclusion HbA1c is an independent predictor of the in-hospital and long-term mortality, nonfatal reinfarction, and target vessel revascularization in STEMI patients treated with primary PCI.

Department of Cardiology, Ankara Numune Education and Research Hospital, Ankara, Turkey

Correspondence to Gökhan Çiçek, MD, Talatpasa Bulvari, 06100 Sihhiye, Ankara, Turkey Tel: +90 312 508 40 00; fax: +90 312 310 34 60; e-mail: drvaristor@hotmail.com

Received May 13, 2016

Received in revised form June 14, 2016

Accepted June 19, 2016

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.